A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.

Feifei Yang,Shihong Peng,Yunqi Li,Liqiang Su,Yangrui Peng,Jing Wu,Huang Chen,Mingyao Liu,Zhengfang Yi,Yihua Chen
DOI: https://doi.org/10.1039/c5ob02250a
2016-01-27
Abstract:A series of novel histone deacetylase (HDAC) inhibitors were designed, synthesized and evaluated based on the strategies of a hybrid of the classic pharmacophore of HDAC inhibitors with the thiazolidinone scaffold. Some of the compounds 12i showed potent HDAC1 inhibition with nM IC50 values, more importantly, compound displayed much better anti-metastatic effects than vorinostat (SAHA) against migration of the A549 cell line. Further mechanism exploration implied that compound 12i may inhibit tumor metastasis via modulating the epithelial-mesenchymal transition (EMT) and upregulating the acetylation of α-tubulin.
What problem does this paper attempt to address?